BEDFORD, Mass. and CAMBRIDGE, Mass. — Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine...
Latest News
BEDFORD, Mass. – Stoke Therapeutics, Inc, a new company working to increase gene expression to treat a wide array of diseases caused by genetic insufficiency, announced that it has completed a $40 million Series A financing to support the further advancement of multiple pre-clinical development programs. The Series A round...
BEDFORD, Mass. – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate...
BEDFORD, Mass. — Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational medicine for the treatment of Autosomal Dominant Optic...
BEDFORD, Mass. – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in Orlando,...
Football, faith and family play very important roles in the life of Davidson College linebacker Storm Monroe. Storm was just 9 years old in 2010 when he was diagnosed with Guillain-Barre syndrome. GBS is a rare disorder in which the body’s immune system attacks the nerves, usually resulting in weakness...
HORSHAM, Pa. — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces a groundbreaking clinical case study published in Case Reports in Oncology. The study reports the successful use of 308-nm excimer laser to treat...
New Brunswick, NJ – Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug – and have devised a strategy that may make the treatment work longer. “This work should help doctors know which patients’ prostate cancers will and won’t respond to the androgen deprivation therapy...
Immune checkpoint inhibitors can boost the immune system’s response to tumor cells, but the medications tend to be ineffective against certain cancers, especially colorectal and pancreatic cancers. A new clinical trial led by investigators at Massachusetts General Hospital (MGH) indicates that combining radiation with immune checkpoint inhibitors may be an...
SOUTH PLAINFIELD, N.J. – PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented real-world results from the STRIDE patient registry demonstrating that treatment with Translarna™ (ataluren) delays loss of ambulation by more than five years in boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) compared to standard of care (SoC) alone. Pulmonary function decline was...